International journal of surgery (London, England) · 2026
Therapeutic potential of liposome@azoramide in cancer by suppressing oxidative phosphorylation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Xin, Xu Zihan, Zeng Yiyao, Meng Xiangyue, Xie Haitong, Zhao Xin, Chen Jie
Аннотация
OBJECTIVE: Targeting cancer cell metabolism represents a promising therapeutic strategy; however, metabolic reprogramming in tumor cells complicates the effectiveness of therapies aimed at disrupting these pathways.
METHODS: This study explored the potential of Azoramide, a compound previously associated with enhanced insulin sensitivity, to modulate cancer metabolism. Azoramide-loaded nano-liposomes (Lip@Azo) were prepared via the thin-film hydration method, chosen for its simplicity and efficiency. We evaluated the anti-tumor efficacy of Lip@Azo and investigated the underlying mechanisms.
RESULTS: We showed that azoramide effectively inhibits tumor growth by suppressing oxidative phosphorylation (OXPHOS) both in vitro and in vivo. Azoramide downregulated OXPHOS proteins, reduced mitochondrial respiration, and induced reactive oxygen species (ROS), leading to decreased mitochondrial ATP generation. Additionally, azoramide downregulated PGC-1α, a key regulator of mitochondrial function, disrupting mitochondrial homeostasis and further impairing tumor cell metabolism, which induced apoptosis and ferroptosis in cancer cells. To enhance the solubility and delivery of azoramide, we encapsulated the compound in liposomes (Lip@Azo), which significantly improved its therapeutic efficacy in vivo.
CONCLUSION: Overall, our findings suggest that Lip@Azo is a promising strategy for targeting mitochondrial metabolism in cancer, offering a new avenue for therapeutic development in oncology.
METHODS: This study explored the potential of Azoramide, a compound previously associated with enhanced insulin sensitivity, to modulate cancer metabolism. Azoramide-loaded nano-liposomes (Lip@Azo) were prepared via the thin-film hydration method, chosen for its simplicity and efficiency. We evaluated the anti-tumor efficacy of Lip@Azo and investigated the underlying mechanisms.
RESULTS: We showed that azoramide effectively inhibits tumor growth by suppressing oxidative phosphorylation (OXPHOS) both in vitro and in vivo. Azoramide downregulated OXPHOS proteins, reduced mitochondrial respiration, and induced reactive oxygen species (ROS), leading to decreased mitochondrial ATP generation. Additionally, azoramide downregulated PGC-1α, a key regulator of mitochondrial function, disrupting mitochondrial homeostasis and further impairing tumor cell metabolism, which induced apoptosis and ferroptosis in cancer cells. To enhance the solubility and delivery of azoramide, we encapsulated the compound in liposomes (Lip@Azo), which significantly improved its therapeutic efficacy in vivo.
CONCLUSION: Overall, our findings suggest that Lip@Azo is a promising strategy for targeting mitochondrial metabolism in cancer, offering a new avenue for therapeutic development in oncology.